Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal Cancer


ONUL117
 
Track 1: Biomarker assessment for patients with metastatic colorectal cancer (mCRC)
Track 2: Perspectives on genomic testing platforms used to perform biomarker analysis for mCRC
Track 3: Role of rebiopsy and repeat biomarker assessment for patients with progressive mCRC
Track 4: Implications of RAS testing for selection of therapy
Track 5: Tumor sidedness and therapeutic decision-making
Track 6: Similarities and differences in the design and primary endpoints of the Phase III CALGB-80405 and FIRE-3 trials evaluating first-line chemotherapy in combination with cetuximab and/or bevacizumab for KRAS wild-type mCRC
Track 7: Prognostic and predictive relevance of primary tumor sidedness in patients with RAS wild-type mCRC on the CALGB-80405 and FIRE-3 trials
Track 8: Efficacy of EGFR inhibitor- versus bevacizumab-based treatments for left- versus right-sided RAS wild-type mCRC
Track 9: Choosing between EGFR inhibitor- and bevacizumab-based treatments as first- and second-line therapy for patients with symptomatic left-sided RAS wild-type mCRC
Track 10: Case (Dr Venook): A woman in her thirties with left-sided RAS wild-type mCRC receives first-line FOLFOXIRI
Track 11: Therapeutic options for younger patients with left-sided RAS wild-type mCRC and disease progression on first-line FOLFOXIRI
Track 12: Case (Dr Bekaii-Saab): A man in his sixties with left-sided RAS wild-type mCRC and disease progression after 2 years of first-line “stop-and-go” FOLFIRI/bevacizumab receives FOLFIRI/panitumumab
Track 13: Activity of cetuximab versus panitumumab and practical considerations for use
Track 14: Clinical experience with and management of EGFR inhibitor-associated dermatologic toxicities
Track 15: Second opinion: Second-line therapy options for patients with left-sided RAS wild-type mCRC and disease progression on first-line FOLFIRI/bevacizumab
Track 16: Faculty perspectives on therapeutic algorithms for first- through later-line therapy for left- versus right-sided RAS wild-type mCRC
Track 17: Efficacy of EGFR inhibition in patients with mCRC and atypical (non-V600E) BRAF mutations
Track 18: Clinical presentation of and prognosis for patients with mCRC and a BRAF V600E tumor mutation
Track 19: Activity and tolerability of EGFR/MEK/BRAF-inhibitor combinations in patients with mCRC and a BRAF V600E tumor mutation
Track 20: Importance of BRAF testing in mCRC; strategies for first-line therapy and beyonds
Track 21: Improved tolerability with triplet EGFR/MEK/BRAF-inhibitor combinations in comparison to anti-EGFR monotherapy or doublet combinations
Track 22: Case (Dr Venook): A woman in her forties with mCRC, a BRAF V600E tumor mutation and rapid disease progression on first-line FOLFOXIRI/bevacizumab attains long-term disease stabilization with encorafenib/binimetinib/panitumumab
Track 23: Case (Dr Bekaii-Saab): A man in his fifties with mCRC and a BRAF V600E tumor mutation receives second-line encorafenib/binimetinib/cetuximab on a clinical trial
Track 24: Assessment of microsatellite instability (MSI) status and tumor mutation burden as predictors of response to immune checkpoint blockade
Track 25: Sequencing of anti-PD-1/PD-L1 checkpoint inhibitors for MSI-high mCRC
Track 26: Neoadjuvant ipilimumab with nivolumab for early-stage colon cancer
Track 27: Activity and tolerability of immune checkpoint inhibitors alone and in combination in patients with MSI-high mCRC
Track 28: Case (Dr Bekaii-Saab): A woman in her fifties with MSI-high, right-sided mCRC and a RAS mutation receives second-line pembrolizumab
Track 29: Case (Dr Venook): A woman in her forties with Stage III CRC initially treated with adjuvant FOLFOX experiences disease progression and receives an assessment of MSI-high disease
Track 30: Perspective on pseudoprogression in patients undergoing immune checkpoint inhibitor therapy
Track 31: Biology and epidemiology of mCRC with HER2 amplification/mutation
Track 32: Activity of and duration of response to dual HER2-targeted therapy in patients with mCRC and HER2 amplification/mutation
Track 33: Therapeutic options for patients with mCRC and HER2 amplification/mutation
Track 34: Case (Dr Venook): A man in his fifties with left-sided, RAS wild-type mCRC and HER2 amplification/mutation receives fourth-line trastuzumab/pertuzumab
Track 35: Case (Dr Bekaii-Saab): A woman in her sixties with left-sided, RAS wild-type mCRC and HER2 amplification/mutation receives third-line trastuzumab/tucatinib on a clinical trial
Track 36: Activity of tucatinib in patients with mCRC and HER2 amplification/mutation
Track 37: Optimizing the risk-benefit ratios of systemic therapy options for patients with mCRC
Track 38: Modulation of the gut microbiome to enhance response to anti-PD-1 immunotherapy; effects of antibiotics on response to immune checkpoint inhibitors
 
FACULTY
 
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of
Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Vice-Chair and Section Lead
Division of Medical Oncology
Medical Director, Cancer Clinical Research Office
Senior Associate Consultant
Mayo Clinic
Phoenix, Arizona
 
Alan P Venook, MD
The Madden Family Distinguished
Professor of Medical Oncology and
Translational Research
University of California, San Francisco
Shorenstein Associate Director
Program Development
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida